Wasatch Advisors LP Has $20.49 Million Position in TransMedics Group, Inc. $TMDX

Wasatch Advisors LP cut its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 10.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 308,434 shares of the company’s stock after selling 37,710 shares during the period. Wasatch Advisors LP’s holdings in TransMedics Group were worth $20,486,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. D.A. Davidson & CO. lifted its position in shares of TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after buying an additional 83 shares during the last quarter. Parallel Advisors LLC grew its position in TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the last quarter. HighPoint Advisor Group LLC grew its position in TransMedics Group by 3.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after acquiring an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after acquiring an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insiders Place Their Bets

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $87.02 on Thursday. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a 50 day simple moving average of $74.90 and a two-hundred day simple moving average of $97.33. The company has a market capitalization of $3.01 billion, a PE ratio of 22.37 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same period in the prior year, the company posted $0.92 earnings per share. The company’s revenue for the quarter was up 20.7% compared to the same quarter last year. Research analysts anticipate that TransMedics Group, Inc. will post 1.47 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMDX shares. TD Cowen reissued a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a report on Wednesday, July 1st. Needham & Company LLC dropped their target price on TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. UBS Group reduced their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.